In a wide-ranging clinical update, East Coast, USA-based gene therapy firm Regenxbio (Nasdaq: RGNX) announced that its pivotal trial program for RGX-314 in wet AMD is now active.
The firm also announced a new program, RGX-202, a novel, potentially best-in-class, one-time gene therapy for the treatment of Duchenne muscular dystrophy (DMD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze